Clinical Trials Still Miss Critical Sex-Based Differences in 2026
Clinical trials continue to underrepresent or under-analyze sex-based biological differences across many therapeutic areas. Although recruitment rules exist, study designs often fail to capture how women respond differently to medicines in terms of safety, dosing, and efficacy.
Furthermore, many trials still rely on aggregated population outcomes. This approach masks clinically relevant differences and reduces the accuracy of treatment evaluation. EMA now identifies this issue as a structural evidence gap that requires regulatory correction rather than voluntary improvement.
EMA Tightens Clinical Trial Requirements for Sex-Based Data Reporting
EMA now increases regulatory scrutiny on how pharmaceutical companies collect and report sex-disaggregated clinical data. The agency will evaluate whether trial designs properly reflect differences in pharmacokinetics, safety profiles, and therapeutic response between men and women.
In addition, EMA will reinforce expectations that product labeling includes sex-specific insights when supported by clinical evidence. This regulatory shift pushes sponsors toward more granular and transparent evidence generation throughout the development lifecycle.
CTIS Data Exposes Systemic Gaps in Women’s Representation Across EU Trials
EMA plans to use the Clinical Trials Information System (CTIS) to analyze demographic distribution across ongoing and completed clinical trials. This deeper data review will help identify where women remain underrepresented in specific therapeutic areas or trial phases.
Moreover, CTIS analysis will allow regulators to evaluate whether current compliance frameworks translate into real-world representativeness. As a result, EMA strengthens its ability to move from procedural compliance toward evidence quality oversight.
Real-World Evidence Becomes a Core Regulatory Tool in Women’s Health
EMA expands the use of real-world evidence through its DARWIN EU network to complement traditional clinical trial data. These studies focus on medicine use patterns, safety signals, and disease epidemiology in populations often underrepresented in trials.
Consequently, regulators can validate trial outcomes against real-world performance and detect risks earlier. This approach also improves understanding of treatment effects in areas such as pregnancy, breastfeeding, and long-term medication use.
Pregnancy and Breastfeeding Data Moves to the Center of Regulatory Focus
EMA intensifies efforts to close evidence gaps related to medicine use during pregnancy and breastfeeding. Historically, clinical trials have excluded these populations due to ethical and methodological limitations, leaving significant uncertainty in safety profiles.
However, new regulatory actions now encourage post-authorisation studies, improved pharmacovigilance systems, and stronger methodological guidance. Additionally, EMA’s support for the ICH E21 guideline signals a structural shift toward safer and more inclusive research practices.
EMA Women’s Health Workshop 2026 Sets the Future Regulatory Agenda
EMA will host a dedicated workshop on women’s health in September 2026, bringing together regulators, researchers, industry leaders, and patient representatives. The workshop aims to map existing evidence gaps and define priority actions for future regulatory development.
Furthermore, the outcomes will directly influence EU-level policy direction in clinical research and medicines regulation. This initiative positions women’s health as a core regulatory priority rather than a secondary consideration in drug development frameworks.
EMA’s 2026 focus on sex-based clinical evidence increases pressure on how clinical data is generated, structured, and validated across systems like CTIS and RWE platforms. This directly ties to data integrity, traceability, and inspection-ready system validation under GMP expectations.
Qualification and Validation for GMP-Regulated Systems supports pharma teams in keeping these systems compliant and aligned with evolving EMA requirements.
Source: Ema.Europa.Eu